Posted on

project cbd fibromyalgia

Project cbd fibromyalgia

This analysis of the prospectively collected data included all patients with diagnosis of fibromyalgia (primary or secondary to other conditions) who initiated treatment with medical cannabis in TO from January 2015 to December 2017. The data were extracted and analyzed retrospectively. The fibromyalgia diagnosis was established by a board-certified rheumatologist according to the American College of Rheumatology preliminary diagnostic criteria for fibromyalgia [13]. Patients were referred to cannabis treatment by ether the family physician, pain physician, or specialized rheumatologist after receiving treatment for at least a year without improvement. The study was approved by the Soroka University Medical Center (SUMC) institutional ethics committee and was conducted by the SUMC Clinical Cannabis Research Institute.

2.1. Study Population

A search of the current literature has identified three randomized controlled trials evaluating the effect of medical cannabis on fibromyalgia-related symptoms. Skrabek et al. enrolled 32 patients to receive nabilone, an orally administered cannabinoid, vs. placebo therapy [10]. At four weeks follow-up there was a significant decrease of 2 points of NRS in addition to improvement in anxiety and overall quality of life. Ware et al. enrolled 29 patients in a trial of nabilone vs. amitriptyline to investigate the effect on sleep disorders among fibromyalgia patients over 2 weeks of therapy. The authors found a moderate effect on insomnia, but not on other aspects of sleep, in addition to no improvement in pain and quality of life [11]. Lastly, Fiz et al. enrolled 56 patients to receive either medical cannabis (the type is not mentioned) or standard therapy [15]. The authors reported a significant effect on pain two hours from consumption, with no effect on quality of life or sleep disorders. Data regarding pain intensity longer than 2 h were not available. Compared to the studies mentioned above, our study has several advantages. First, our study represents a real-world experience of herbal cannabis use in the cohort of patient with fibromyalgia. Second, we have assessed a substantially larger cohort of 367 fibromyalgia patients with six months follow-up of 211 patients (vs. 30–56 patients in previous studies). Our data also provided a relatively long follow-up of six months periods (compared to only several weeks follow up), which allowed us to analyze the effect and safety of medical cannabis on fibromyalgia patients over an extended period of time. Lastly, we studied the effect of medical cannabis on every aspect of fibromyalgia: improvement in chronic pain, quality of life, disease perception and specific symptoms, and the incidence of adverse effects.

4. Discussion

I.S., L.B.-L.S., and V.N. are responsible for study conception and design. L.B.-L.S. extracted the data. I.S. Drafted the manuscript and conducted the statistical analysis. L.B.-L.S., M.A.-S. and V.N. gave critical revisions.

Project cbd fibromyalgia

His expertise touches upon every area of pain; from spinal, musculoskeletal and nerve pain to post-surgical and trauma pain, and many areas of cancer related pain. Dr Ordman is also involved in pain management for rehabilitation and functional restoration after injury or serious illness. His belief in a patient-centred approach, sensitive to the individual needs of each person has had a strong influence on the Integro patient experience.

Dr Anthony Ordman Lead Clinician at Integro Clinics – Founder of the highly respected Chronic Pain Clinic at London’s Royal Free Hospital, Dr Anthony Ordman is one of the UK’s most experienced specialists in the treatment of pain. For his contributions to Pain Medicine Dr Ordman was awarded Fellowship of the Royal College of Physicians in 2005, and he is Immediate past President of the Pain Medicine Section of the Royal Society of Medicine.

Part 1: 2nd November 2021

Aimed at patients and carers of those living with fibromyalgia and arthritis, and healthcare professionals with a particular interest in these conditions, this event hopes to shed light on the lived experience of these patient groups and how newly available prescribed cannabis medicines have the potential to revolutionise the management of this conditions.

Mary Biles – Mary Biles is the author of ‘The CBD Book: The Essential Guide to CBD Oil’, regular contributing writer for Californian educational non-profit Project CBD and host of the podcast Cannabis Voices. Mary is respected within the industry for her ability to create engaging content that explains in digestible terms the science behind cannabis and CBD in a way that patients and consumers understand and can relate to. As Chief Editor of CPASS, Mary is committed to furthering the education of nurses interested in medical cannabis through the organisation’s Nurse’s Arm as well as supporting patients on their cannabis journey.

Part 2: 9th November 2021

Steven Spencer – Steven first developed FSH Muscular Dystrophy in 2014, and was diagnosed in 2016 after an incorrect diagnosis of Brachial Neuritis. Then in 2015, he developed fibromyalgia, diagnosed 2016, which restricted him to a wheelchair when outside his home. He also lives with dyspraxia (diagnosed in 2001), ADHD (diagnosed 2016) and dyslexia (diagnosed 2021). He has also been diagnosed with PTSD (diagnosed 2020 not a full diagnosis because the current medication is treating some of the symptoms) and IBS (2020) but had symptoms of both of these since 2015.